The objective of the study was to determine if DSM-5–defined attenuated psychosis syndrome (APS) could identify individuals with prodromal psychosis and predict conversion to schizophrenia spectrum disorders at a rate similar to that observed in previous studies that utilized structured interviews and specialized rating scales.
Methods
A retrospective review of patients’ medical records was used to identify individuals meeting diagnostic criteria for the APS, followed by further evaluation 2 to 3 years after the initial diagnosis, to determine if they converted to schizophrenia spectrum disorders. Results then were compared with previous studies.
Results
Of our study population, 43.4% converted to schizophrenia or schizoaffective disorder 2 to 3 years after initial diagnosis of APS. Comparison at the 3-year mark indicated that there was no significant difference between our observed rates and previously published conversion rates (P = .066). Three covariates were found to increase significantly the rates of conversion when added to the APS criteria: Cannabis use (P = .048), lack of previous Axis I diagnosis (P = .005), and lack of previous treatment with psychotropic medications (P = .009).
Conclusions
APS accurately predicts conversion to full-scale schizophrenia spectrum disorders at a rate similar to that observed in previous studies using structured interviews and specialized rating scales.
Get full access to this article
View all access options for this article.
References
1.
RegierDA, NarrowWE, RaeDS, . The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85–94.
2.
TandonR, KeshavanMS, NasrallahHA.Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102:1–18.
3.
WuEQ, BirnbaumHG, ShiL, . The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry.2005;66:1122–1129.
4.
NichollD, AkhrasKS, DielsJ, . Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26:943–955.
5.
NormanRM, LewisSW, MarshallM.Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry Suppl. 2005;48: s19–23.
6.
PerkinsDO, GuH, BotevaK, . Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785–1804.
7.
MarshallM, LewisS, LockwoodA, . Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975–983.
8.
SarotarBN, PesekMB, AgiusM, . Duration of untreated psychosis and it's effect on the functional outcome in schizophrenia - preliminary results. Psychiatr Danub. 2008;20:179–183.
9.
HegelstadW T, LarsenTK, AuestadB, . Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169:374–380.
10.
McGlashanTH.Early detection and intervention of schizophrenia: rationale and research. Br J Psychiatry Suppl. 1998;172:3–6.
11.
KlosterkötterJ, RuhrmannS, Schultze-LutterF, . The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4:161–167.
12.
AddingtonJ, CadenheadKS, CannonTD, ; North American Prodrome Longitudinal Study. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33:665–672.
13.
AddingtonJ, CadenheadKS, CornblattBA, . North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophr Res. 2012;142:77–82.
14.
CannonTD, CadenheadK, CornblattB, . Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65:28–37.
15.
MillerTJ, McGlashanTH, RosenJL, . Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703–715.
16.
RuhrmannS, Schultze-LutterF, SalokangasRK, . Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67:241–251.
17.
WoodsSW, AddingtonJ, CadenheadKS, . Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35:894–908.
18.
YungAR, YuenH P, McGorryPD, . Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39:964–971.
19.
YungAR, NelsonB, StanfordC, . Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105:10–17.
20.
TandonN, ShahJ, KeshavanMS, . Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry (London). 2012;2:345–353.
21.
Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
22.
CarpenterW T, van OsJ.Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry. 2011;168:460–463.
23.
TsuangMT, Van OsJ, TandonR, . Attenuated psychosis syndrome in DSM-5. Schizophr Res. 2013;150:31–35.
24.
WoodsSW, WalshBC, SaksaJR, . The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophr Res. 2010;123:199–207.
25.
CorcoranCM, FirstMB, CornblattB.The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res. 2010;120:16–22.
26.
YangLH, Wonpat-BorjaAJ, OplerMG, . Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr Res. 2010;120:42–48.
27.
Fusar-PoliP, BorgwardtS, BechdolfA, . The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107–120.
28.
WoodsS, WalshB, McGlashanT.Diagnostic reliability and validty of the proposed DSM-5 attenuated psychosis syndrome [abstract]. Early Interv Psychiatry. 2012;6:(suppl 1)33.
29.
RegierDA, NarrowWE, ClarkeDE, . DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry. 2013;170:59–70.
30.
TandonR, CarpenterWTJr. DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull. 2012;38:369–370.
31.
CarpenterWT.Attenuated psychosis syndrome: need for debate on a new disorder. Psychopathology. 2014;47:287–291.
32.
Fusar-PoliP, CarpenterW T, WoodsSW, . Attenuated psychosis syndrome: ready for DSM-5. 1? Annu Rev Clin Psychol. 2014;10:155–192.
33.
Fusar-PoliP, BonoldiI, YungAR, . Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012;69:220–229.
34.
MakiP, VeijolaJ, JonesPB, . Predictors of schizophrenia—a review. Br Med Bull. 2005;73–74:1-15.
35.
MortensenPB, PedersenCB, WestergaardT, . Effects of family history and place and season of birth on the risk of schizophrenia. N Engl J Med. 1999;340:603–608.
36.
SPSS Statistics [computer program]. Version 22. Armonk, NY: IBM Corp.; 2013.
37.
KesslerRC, BorgesG, WaltersEE.Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56:617–626.
38.
United States Census Bureau. South Carolina state and county quick facts. 2015; quickfacts.census.gov/qfd/states/45000.html. Accessed September 15, 2015.
39.
JablenskyA.Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250:274–285.
40.
MinskyS, VegaW, MiskimenT, . Diagnostic patterns in Latino, African American, and European American psychiatric patients. Arch Gen Psychiatry. 2003;60:637–644.
41.
NeighborsHW, JacksonJS, CampbellL, . The influence of racial factors on psychiatric diagnosis: a review and suggestions for research. Community Ment Health J. 1989;25:301–311.
42.
ZammitS, AllebeckP, AndreassonS, . Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199.
43.
HenquetC, MurrayR, LinszenD, . The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31:608–612.
44.
SmitF, BolierL, CuijpersP.Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99:425–430.
45.
HamnerMB, FruehBC, UlmerHG, . Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry. 1999;45:846–852.
46.
WigmanJT, van NieropM, VolleberghWA, . Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity—implications for diagnosis and ultra-high risk research. Schizophr Bull. 2012;38:247–257.
47.
ChambersWJ, Puig-AntichJ, TabriziMA, . Psychotic symptoms in prepubertal major depressive disorder. Arch Gen Psychiatry. 1982;39:921–927.
48.
MantelN, HaenszelW.Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748.
49.
HessDR.Retrospective studies and chart reviews. Respir Care. 2004;49:1171–1174.
50.
SartwellPE.Retrospective studies. A review for the clinician. Ann Intern Med. 1974;81:381–386.
51.
Fusar-PoliP, BechdolfA, TaylorMJ, . At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull. 2013;39:923–932.
